At a moment when public health systems everywhere are asked to do more with less, England's NHS has reached a new threshold: £17.2 billion spent on prescription medicines in a single year, driven not by volume alone but by the rising price of a relatively small number of hospital drugs. Researchers from three leading institutions are asking a question that sits at the heart of modern medicine's social contract — not whether new treatments work, but whether their cost reflects their true worth to patients and the communities that fund their care. As the UK government renegotiates its pricing ag
NHS prescription drug costs hit £17.2bn record, driven by cancer and respiratory medicines
Every pound spent on expensive medicines is a pound unavailable for other treatments.
Mark
So the NHS spent £17.2 billion on prescription medicines last year. That's a record. But is that surprising? Doesn't healthcare spending always go up?
Mimi
It does, but not at this rate. Branded medicine spending has grown over five percent annually since 2018. That's faster than the overall NHS budget. And it's concentrated in a few drug categories—cancer and respiratory medicines especially.
Luke
But we should be careful here. The source excludes COVID vaccines and treatments. So we don't know what the actual total pharmaceutical bill was. And five percent annual growth—is that unusual for new cancer drugs? The report doesn't compare it to historical trends or other countries.
Mimi
Fair point. What the report does show is that hospital medicines nearly doubled in four years, from £6.7 billion to £9.1 billion. And a small number of products drove most of that increase.
Mark
Which products? Are we talking about breakthrough drugs that genuinely save lives, or are these expensive me-too medicines?
Mimi
The report doesn't name the specific drugs. It just says the top three respiratory medicines accounted for £561 million in new spending, and the top three cancer drugs for £333 million.
Luke
That's a limitation. Without knowing which drugs these are, we can't assess whether the price increases reflect genuine innovation or just market power. The researchers argue many new medicines are overpriced, but that's their judgment, not a fact we can independently verify.
Mark
The pharmaceutical industry says the current pricing agreement discourages them from launching drugs in Britain. Does the report address that?
Mimi
It does. The researchers argue the NHS is still an attractive market because the regulator is fast, NICE recommends most new drugs, and new medicines get a three-year exemption from the pricing cap anyway.
Luke
But that's a rebuttal, not evidence. We don't have data on how many drugs were actually delayed or not launched because of pricing concerns. The industry's claim and the researchers' counterargument are both plausible, and the report doesn't settle it.
Mark
So what's actually at stake in the government's renegotiation?
Mimi
Whether the NHS continues to pay premium prices for medicines, or whether it pushes back harder on pricing to free up money for other services. The researchers think current prices are too high relative to the health benefits.
Luke
And the government has to weigh that against the industry's argument that lower prices might reduce investment in UK drug development. Both sides have a point, and the report is clearly arguing one side of that debate.
Il Polso
- NHS prescription spending has hit £17.2 billion — a record driven by hospital medicines that have surged 35% in just four years, outpacing the health service's own budget growth.
- A handful of cancer, immunosuppressant, and respiratory drugs account for the bulk of new spending, raising urgent questions about whether a few products are consuming resources meant for the many.
- Researchers warn that every pound overpaid for a drug is a pound taken from other proven NHS services, framing pharmaceutical pricing as a direct threat to the breadth of care available to patients.
- The pharmaceutical industry argues that pricing pressure discourages UK drug launches and undermines Britain's status as an innovation hub — claims the researchers say the evidence does not support.
- With the current voluntary pricing agreement expiring, the UK government faces a high-stakes renegotiation that will determine how the value of new medicines is divided between industry profit and public benefit.
At a moment when public health systems everywhere are asked to do more with less, England's NHS has reached a new threshold: £17.2 billion spent on prescription medicines in a single year, driven not by volume alone but by the rising price of a relatively small number of hospital drugs. Researchers from three leading institutions are asking a question that sits at the heart of modern medicine's social contract — not whether new treatments work, but whether their cost reflects their true worth to patients and the communities that fund their care. As the UK government renegotiates its pricing agreement with the pharmaceutical industry, the answer will shape not only what medicines the NHS can afford, but what else it cannot.
England's NHS spent £17.2 billion on prescription medicines in 2021-2022 — a record figure, and one that excludes COVID-19 vaccines and treatments entirely. The research, produced by teams at the London School of Economics, the London School of Hygiene and Tropical Medicine, and the University of York, reveals that branded medicine costs have grown by more than five percent annually since 2018, a pace that consistently outstrips the health service's overall budget.
The sharpest increases have come from hospitals. Between 2018 and 2022, hospital medicine spending rose from £6.7 billion to £9.1 billion — a 35 percent climb. Cancer drugs and immunosuppressants added £904 million to the bill over that period, while respiratory medicines surged by 279 percent, contributing £587 million in new spending. In both categories, just three products accounted for the overwhelming majority of growth.
The researchers' concern is not with the medicines themselves but with their pricing. Dr. James Lomas of the University of York put it directly: the NHS has finite resources, and money spent on overpriced drugs is money unavailable for treatments that already deliver clear value. The question, he argued, is not whether a drug works — but whether its price is proportionate to what it actually delivers.
This debate arrives as the UK government renegotiates the Voluntary Scheme for Branded Medicines Pricing and Access, the agreement that caps annual branded medicine sales to the NHS and requires rebates when that cap is exceeded. The pharmaceutical industry has warned that tighter pricing could discourage companies from launching drugs in Britain and reduce investment in innovation. The researchers pushed back, noting that the UK's fast regulatory approval process and high NICE recommendation rates make it an attractive market regardless — and that new drugs already receive a three-year exemption from the pricing cap.
Dr. Beth Woods argued that the current arrangement grants industry too large a share of the value medicines create, while Dr. Aris Angelis urged the government to ensure medicine spending remains proportionate so that other NHS services are not quietly hollowed out. Senior author Dr. Huseyin Naci cautioned against using drug pricing as industrial policy, suggesting that other tools would better serve both innovation and public health. The outcome of these negotiations will determine, in practical terms, what the NHS can afford to offer — and what it cannot.
The bill for prescription medicines across the NHS in England climbed to £17.2 billion in the 2021-2022 financial year, marking a new peak, according to research released by teams at the London School of Economics, the London School of Hygiene and Tropical Medicine, and the University of York. The figure excludes spending on COVID-19 vaccines and treatments. What makes this number significant is not just its size but the speed at which it arrived: since 2018, spending on branded medicines has grown by more than five percent annually, a rate that outpaces the health service's overall budget growth.
The surge has been driven largely by hospital-prescribed medicines, which nearly doubled in cost over four years. In 2018, hospitals spent £6.7 billion on medicines. By 2022, that figure had climbed to £9.1 billion—a 35 percent increase. Two drug categories account for much of this acceleration. Cancer medicines and immunosuppressants grew by 43 percent, adding £904 million to the medicines bill since 2018. Respiratory drugs surged even more dramatically, jumping 279 percent and contributing £587 million in additional spending. What's striking is that a handful of products in each category drove most of this growth. The top three respiratory medicines alone accounted for £561 million of new spending between 2018 and 2022. The top three cancer drugs represented £333 million.
Researchers examining these trends found reason for concern. Many new medicines, they concluded, are priced too high relative to the actual health benefits they deliver to patients. Dr. James Lomas of the University of York framed the problem plainly: the NHS operates with finite resources, and every pound spent on expensive medicines is a pound unavailable for other treatments and services that already demonstrate significant value. The question becomes not whether a drug works, but whether its price reflects what it's worth.
This analysis arrives as the UK government renegotiates its voluntary pricing agreement with the pharmaceutical industry. The current scheme, known as the Voluntary Scheme for Branded Medicines Pricing and Access, sets an annual cap on total branded medicine sales to the NHS. Under the existing terms, which expire this year, the cap grows at two percent annually, and any sales exceeding the cap trigger rebates to the government. The pharmaceutical industry has argued that this arrangement may discourage companies from launching new drugs in Britain, harm the UK's standing as a hub for drug development, and reduce investment in innovation.
The researchers countered that these concerns may be overstated. The NHS remains an attractive market for pharmaceutical companies regardless of pricing pressure. Britain's medicines regulator, the MHRA, ranks among the world's fastest. The National Institute for Health and Care Excellence, which evaluates new drugs, recommends most medicines it assesses for NHS use. Additionally, new drugs already receive a three-year exemption from the pricing cap after launch. There is no evidence, the report states, that the price the NHS pays for medicines significantly influences where pharmaceutical companies choose to invest in research and development.
Dr. Beth Woods of the University of York argued that the balance has tipped too far toward industry profits. Incentivizing innovation matters, she said, but the current arrangement gives pharmaceutical companies too large a share of the value their medicines create. The right approach requires splitting that value—rewarding industry for developing new treatments while ensuring patients and the health service capture genuine health benefits. Dr. Aris Angelis of the London School of Hygiene and Tropical Medicine urged the government to ensure that medicine spending remains proportionate during negotiations, preventing resources from being diverted from other critical NHS services at a time when budgets are already strained.
The researchers also noted that recent economic analyses suggest current UK medicine prices are likely higher than necessary to sustain pharmaceutical innovation. Dr. Huseyin Naci, the report's senior author, cautioned against using pricing as the primary tool for industrial policy. Other mechanisms, he suggested, would be more effective. As the government enters negotiations with the pharmaceutical industry over the next pricing agreement, these findings will shape the debate over how much the NHS should pay for the medicines it prescribes.
Citazioni salienti
The NHS does not have unlimited resources and the more money we spend on medicines, the less money we have for other medicines, treatments and services that already offer significant health benefits.— Dr. James Lomas, University of York
The pharmaceutical industry is currently getting too big of a slice of the pie.— Dr. Beth Woods, University of York
Vuoi la storia completa?
Leggi l'originale su News-Medical.net ↗
Health & Medicine